Skip to main content
SpringerLink
Log in

Opinion and Evidence in Neurology and Psychiatry

  • From the World Literature
  • Published:
CNS Drugs Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Notes

  1. Buprenorphine was administered on a daily basis under supervision for at least 6 months but could be administered as ‘take-home’ doses thereafter. Patients randomised to the placebo group received a tapered 6-day regimen of buprenorphine and placebo thereafter.

  2. The recombinant interferons used in the studies were interferon-β−1b, interferon-β−1a and interferon-α−2a.

  3. Trial of ORG 10172 in acute stroke treatment.

  4. Rapid Anticoagulation Prevents Ischemic Damage.

  5. Selegiline was initiated at a dose of 5mg once daily for 7 days and increased to 5mg twice daily on day 8. Subsequently, selegiline was tapered to 5mg once daily during week 9 and discontinued thereafter.

  6. 7-day point prevalence smoking abstinence was defined as no smoking reported in the 7 days up to and including the day of assessment.

  7. The dosage of testosterone gel was reduced to 7.5g if morning serum testosterone levels exceeded 1070 ng/dL at the end of week 1.

  8. Costs (1999 Canadian dollars) were those associated with drug acquisition, procedures, physician visits, stimulator acquisition, dyskinesia diagnosis and management, hospitalisation, nursing home care, caregiver time and time lost from work for patients aged <60 years. Costs were discounted at 3% and 5% per annum and were assessed from the perspectives of society and the Ministry of Health, Ontario.

  9. A total of two stimulant-naive patients received standard methylphenidate therapy to validate the study design.

  10. A lapse was defined as the first drink after detoxification. Relapse was defined as five or more standard drinks per day for men and four or more standard drinks per day for women or five or more drinking days per week.

References

  1. Kakko J, Svanborg KD, Kreek MJ, et al. 1-year retention and social function after buprenorphine-assisted relapse prevention treatment for heroin dependence in Sweden: a randomised, placebo-controlled trial. Lancet 2003 Feb 22; 361: 662–8

    Article  PubMed  CAS  Google Scholar 

  2. Law FD, Nutt DJ. Maintenance buprenorphine for opioid users. Lancet 2003 Feb 22; 361: 634–5

    Article  PubMed  Google Scholar 

Reference

  • Geddes JR, Carney SM, Davies C, et al. Relapse prevention with antidepressant drug treatment in depressive disorders: a systematicreview. Lancet 2003 Feb 22; 361: 653–61

    Article  PubMed  CAS  Google Scholar 

Reference

  • Filippini G, Munari L, Incorvaia B, et al. Interferons in relapsing remitting multiple sclerosis: a systematic review. Lancet 2003 Feb 15; 361: 545–52

    Article  PubMed  CAS  Google Scholar 

Reference

References

  1. Donnan GA, Davis SM. Heparin in stroke: not for most, but the controversy lingers. Stroke 2003 Jan; 34: 232–3

    Article  PubMed  Google Scholar 

  2. Caplan LR. Resolved: heparin may be useful in selected patients with brain ischemia. Stroke 2003 Jan; 34: 230–1

    Article  PubMed  Google Scholar 

  3. Sandercock P. Full heparin anticoagulation should not be used in acute ischemic stroke. Stroke 2003 Jan; 34; 231–2

    Article  PubMed  Google Scholar 

Reference

  • Algra A, De Schryver ELLM, van Gijn J, et al. Oral anticoagulants versus antiplatelet therapy for preventing further vascular events after transient ischemic attack or minor stroke of presumed arterial origin. Stroke 2003 Jan; 34: 234–5

    Article  PubMed  CAS  Google Scholar 

Reference

  • George TP, Vessicchio JC, Termine A, et al. A preliminary placebo-controlled trial of selegiline hydrochlroide for smoking cessation. Biol Psychiatry 2003 Jan 15; 53: 136–43

    Article  PubMed  CAS  Google Scholar 

Reference

  • Pope JR HG, Cohane GH, Kanayama G, et al. Testosterone gel supplementation for men with refractory depression: a randomized, placebo-controlled trial. Am J Psychiatry 2003 Jan; 160: 105–11

    Article  PubMed  Google Scholar 

Reference

Reference

  • Iskedjian M, Einarson TR. Cost analysis of ropinirole versus levodopa in the treatment of Parkinson’s disease. Pharmacoeconomics 2003;21(2): 115–27

    Article  PubMed  Google Scholar 

Reference

  • Spencer T, Heiligenstein JH, Biederman J, et al. Results from 2 proof-of-concept, placebo-controlled studies of atomoxetine in children with attention-deficit/hyperactivity disorder. J Clin Psychiatry 2002 Dec; 63: 1140–7

    Article  PubMed  CAS  Google Scholar 

References

  1. Kiefer F, Jahn H, Tarnaske T, et al. Comparing and combining naltrexone and acamprosate in relapse prevention of alcoholism. Arch Gen Psychiatry 2003 Jan; 60: 92–9

    Article  PubMed  CAS  Google Scholar 

  2. Gastpar M, Bonnet U, Böning J, et al. Lack of efficacy of naltrexone in the prevention of alcohol relapse: results from a German multicenter study. J Clin Psychopharmacol 2002 Dec; 22: 592–8

    Article  PubMed  CAS  Google Scholar 

Reference

  • Cornfield DN, Tegtmeyer K, Nelson MD, et al. Continuous propofol infusion in 142 critically ill children. Pediatrics 2002 Dec; 110 (Pt 1): 177-81

Download references

Rights and permissions

Reprints and permissions

About this article

Cite this article

Opinion and Evidence in Neurology and Psychiatry. CNS Drugs 17, 363–370 (2003). https://doi.org/10.2165/00023210-200317050-00005

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00023210-200317050-00005

Search

Navigation